RADIATION THERAPY ONCOLOGY GROUP
RTOG 1010
A PHASE III TRIAL EVALUATING THE ADDITION OF TRASTUZUMAB TO TRIMODALITY TREATMENT OF HER2-OVEREXPRESSING ESOPHAGEAL ADENOCARCINOMA
RTOG 1010
A PHASE III TRIAL EVALUATING THE ADDITION OF TRASTUZUMAB TO TRIMODALITY TREATMENT OF HER2-OVEREXPRESSING ESOPHAGEAL ADENOCARCINOMA
Protocol Participation Information
- Credentialing
- Facility Questionnaire: Part I and Part III are required for this protocol.
- A test of digital data submission is required for institutions that have not previously submitted external beam treatment planning data to the ITC. The treatment planning system to be used to plan patients on the study should be used for this digital data submission test. Please contact the ITC (itc@wustl.edu) for questions regarding digital data submission and to request an SFTP account, if you do not have one already.
- How to Participate
- Protocol Text (http://www.rtog.org)
Cases with case numbers above 329 are to be submitted via TRIAD at RTOG HQ. Please see section 12.2 of the protocol for information on TRIAD.
Back to protocols
